MARKET

TYRA

TYRA

Tyra Biosciences, Inc.
NASDAQ
36.51
+0.32
+0.88%
Pre Market: 36.51 0 0.00% 04:26 05/15 EDT
OPEN
36.03
PREV CLOSE
36.19
HIGH
37.03
LOW
35.17
VOLUME
15
TURNOVER
0
52 WEEK HIGH
40.65
52 WEEK LOW
8.75
MARKET CAP
2.17B
P/E (TTM)
-18.1416
1D
5D
1M
3M
1Y
5Y
1D
Jefferies Reaffirms Their Buy Rating on Tyra Bioscience (TYRA)
TipRanks · 17h ago
Bank of America Securities Keeps Their Buy Rating on Tyra Bioscience (TYRA)
TipRanks · 18h ago
Analysts Offer Insights on Healthcare Companies: Tyra Bioscience (TYRA) and MDxHealth (MDXH)
TipRanks · 18h ago
Wedbush Keeps Their Buy Rating on Tyra Bioscience (TYRA)
TipRanks · 20h ago
Tyra Biosciences Price Target Maintained With a $45.00/Share by HC Wainwright & Co.
Dow Jones · 21h ago
H.C. Wainwright Keeps Their Buy Rating on Tyra Bioscience (TYRA)
TipRanks · 22h ago
HC Wainwright & Co. Reiterates Buy on Tyra Biosciences, Maintains $45 Price Target
Benzinga · 22h ago
Tyra Bioscience (TYRA) Gets a Buy from Barclays
TipRanks · 23h ago
More
About TYRA
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target large opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables precise drug design through iterative molecular SNAPshots that help predict genetic alterations to cause acquired resistance to existing therapies. It has a differentiated pipeline with three product candidates in clinical development in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, TYRA-300, is a potential selective FGFR3 inhibitor that is designed to avoid the toxicities associated with inhibition of FGFR1, FGFR2 and FGFR4, while being agnostic for the FGFR3 gatekeeper mutations. It is also developing TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in the SURF201 study for metastatic intrahepatic cholangiocarcinoma, and TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers.

Webull offers Tyra Biosciences Inc stock information, including NASDAQ: TYRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TYRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TYRA stock methods without spending real money on the virtual paper trading platform.